Loss of entrainment of high-frequency plasma insulin oscillations in type 2 diabetes is likely a glucose-specific beta-cell defect.
Spontaneous high-frequency insulin oscillations are easily entrainable to exogenous glucose in vitro and in vivo, but this property is lost in type 2 diabetes (2-DM). We hypothesized that this lack of entrainment in 2-DM would be specific to glucose. This was tested in nine control and ten 2-DM subjects. Serial blood sampling at 1-min intervals was carried out for 60 min in the basal state and for 120 min while small (1-60 mg/kg) boluses of arginine were injected intravenously at exactly 29-min intervals. Samples were analyzed for insulin concentrations, and time series analysis was carried out using spectral analysis. In control subjects, the mean period of basal plasma insulin oscillations was 10.3 +/- 1.3 min and was entrained by arginine to a mean period of 14.9 +/- 0.6 min (P < 0.00001 vs. basal). Similarly, in 2-DM subjects, spontaneous insulin oscillations were entrained by arginine; mean basal insulin period was 10.0 +/- 1.0 min and 14.5 +/- 1.8 min with arginine boluses (P < 0.00001). All of the primary peaks observed in spectral analysis were statistically significant (P < 0.05). Percent total power of primary peaks ranged from 17 to 68%. Thus arginine boluses entrain spontaneous high-frequency insulin oscillations in 2-DM subjects. This represents a distinct and striking difference from the resistance of the beta-cell to glucose entrainment in 2-DM. We conclude that loss of entrainment of spontaneous high-frequency insulin oscillations in 2-DM is likely a glucose-specific manifestation of beta-cell secretory dysfunction.
Harbor-UCLA Medical Center, Box 16, 1000 W. Carson St., Torrance, CA 90509-2910, USA.
Catherine S
CS
Mao
Nancy
N
Berman
Eli
E
Ipp
D000328:Adult; D000368:Aged; D001120:Arginine / Q000008:administration & dosage*; D001683:Biological Clocks / Q000187:drug effects*; D001786:Blood Glucose / Q000032:analysis* / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood*; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009991:Oscillometry / Q000379:methods; D010507:Periodicity
D001786:Blood Glucose; D007328:Insulin; D001120:Arginine; D005947:Glucose